Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccinationArticle Published on 2022-09-012022-11-15 Journal: RMD Open [Category] SARS, 진단, [키워드] activated Activation antibody Autoimmune Autoimmune diseases Cellular immune response cellular response Combination correlated COVID-19 COVID-19 vaccination csDMARD cytokine cytokine profile drug drugs evaluated female first vaccination Frequency Heterologous highest humoral IgG immunosuppressive immunosuppressive therapy Inflammatory inhibitor investigated majority marker median age medications methotrexate monotherapy mRNA-based vaccine MTX Neutralising Antibodies neutralising antibody no difference not significant outcome Patient psoriatic arthritis quantification receiving rheumatic disease rheumatoid arthritis SARS-CoV-2 second vaccination Seroconversion spike-protein spondyloarthritis T-cell T-cell immunity T-lymphocyte T-lymphocyte subsets Therapies therapy titre treated vaccination [DOI] 10.1136/rmdopen-2022-002293 PMC 바로가기
A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipientsBNT162b2 mRNA 백신의 세 번째 접종은 간 이식 환자의 면역 반응을 크게 향상시킵니다Article Published on 2022-09-012022-09-12 Journal: Journal of hepatology [Category] Fulltext, MERS, 진단, [키워드] Adverse adverse effect adverse effects age Anti-RBD IgG anti-SARS-CoV-2 antibody Antibody Response binding domain BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine Booster vaccine cellular immune responses cellular response center correlated determine dose doses Effect evaluate evaluated Factor fatigue Follow-up geometric humoral humoral immune response IgG immune immune response Immunity Immunosuppression immunosuppressive medications IMPROVE inhibitor liver liver transplant recipients local pain majority male median age Mild monotherapy neutralizing antibody Older age Patient predict RBD recipient recipients reported response Side effect side effects BNT162b2 mRNA vaccine significantly solid organ transplant T-cell the patient third dose Treatment Vaccine vaccine dose [DOI] 10.1016/j.jhep.2022.03.042 PMC 바로가기 [Article Type] Article
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritisClinical Science Published on 2022-08-032024-09-04 Journal: Rheumatology (Oxford, England) [Category] 대상포진, [키워드] Janus kinase inhibitor monotherapy psoriatic arthritis Upadacitinib [DOI] 10.1093/rheumatology/keab905 PMC 바로가기 [Article Type] Clinical Science
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273SARS-CoV-2의 면역 역학은 면역 억제된 류마티스 관절염 또는 mRNA-1273 예방 접종을 받은 다발성 경화증 환자를 경험했습니다.Article Published on 2022-07-152022-09-12 Journal: eLife [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] absence acute respiratory syndrome affected analyzed anti-CD20 antibody Autoimmune Autoimmune disease Autoimmune diseases B cell response benefit CD4 CD8 Cell cellular cellular immunity central memory circulating condition coronavirus COVID-19 COVID-19 mRNA vaccine development disease Disease activity European European Commission first vaccination flow cytometry follicular HCs healthy control Horizon Human humanized humoral Humoral immunity IgG immune immune response Immunity immunology Immunosuppressant immunosuppressants Immunosuppressed increased risk Infection Inflammation leadership longitudinal marker Medicine methotrexate Moderna monoclonal antibody monotherapy mRNA mRNA-1273 MTX multiple sclerosis Netherland organization outcome Patient patients treated preserved recall Research resulting rheumatoid arthritis SARS-CoV-2 second vaccination shielding significantly supported suppress sustained T cell T cell response T cells T helper the SARS-CoV-2 treated Treatment union vaccination Vaccine vulnerable patients whole blood sample [DOI] 10.7554/eLife.77969 PMC 바로가기 [Article Type] Article
Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease종양 괴사 인자-α 길항제의 사용은 염증성 장 질환이 있는 백신 접종 환자에서 SARS-CoV-2에 대한 약화된 IgG 항체 반응과 관련이 있습니다Observational Study Published on 2022-07-052022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Against age antagonist antagonists anti-SARS-CoV-2 antibody anti-SARS-CoV-2 vaccination antibody Antibody concentrations Antibody titer Antibody titers Biologicals Blood blood sampling bowel Characteristics clinical Clinical characteristics Combination completion Concentration COVID-19 Crohn's disease defined demonstrated detectable disease Effect elapsed geometric geometric mean IBD IgG IgG antibodies IgG antibody IgG antibody titer IgG antibody titers immune response immunoassay immunomodulating Immunosuppressive medication immunosuppressive medications increased risk independent independent of Inflammatory Inflammatory bowel disease medication Microparticle monotherapy Most patients mRNA mRNA vaccines mRNA-based vaccine mRNA-based vaccines Multivariable models Patient patient age patients patients treated prospective observational cohort quantitative determination RBD receive receiving Receptor-binding domain regimen response S1 subunit sampling SARS-CoV-2 SARS-COV-2 infection Seroconversion serological response significantly lower Spike protein the receptor-binding domain the S1 subunit the spike protein titer TNF-α-antagonists treated Treatment Tumor ulcerative colitis vaccination Vaccine vector was used were measured were recorded [DOI] 10.3389/fimmu.2022.920333 PMC 바로가기 [Article Type] Observational Study
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strainsSARS-CoV-2 Omicron 계통 균주에 의한 감염에 대한 S309 및 AZD7442 단일클론 항체 치료의 회복력Article Published on 2022-07-022022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acting Antibody neutralization AstraZeneca Cell culture changes in Combination correlation analyses Correlation analysis Effect Efficacy Express FcγR hACE2 human ACE2 humans in vitro In vitro studies in vitro study in vivo Infection Interaction K18-hACE2 Lineage Lung infection mAb mechanism mice monoclonal antibody monoclonal antibody therapies monoclonal antibody treatment monotherapy neutralization neutralization potency Neutralizing activity omicron Omicron variant Omicron variants Prevent Prophylactic Protective reduced reductions reductions in Resilience retained S309 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 isolates SARS-CoV-2 variant Spike protein strain suggested susceptible the spike protein therapeutic therapy transgenic mice treat Treatment variant variants Viral viral burden [DOI] 10.1038/s41467-022-31615-7 PMC 바로가기 [Article Type] Article
Internet psychotherapeutic interventions for anxiety disorders – a critical evaluation불안 장애에 대한 인터넷 심리 치료 중재 - 비판적 평가Review Published on 2022-06-292022-09-11 Journal: BMC Psychiatry [Category] 임상, [키워드] Affect agoraphobia antianxiety Anxiety Anxiety Disorder anxiety disorders approach Arm behavioural clinical settings cognitive Comparisons conducted Contact contact with control condition controls COVID-19 pandemic Critical diagnose diagnoses disorder drug effect size effective Generalised anxiety disorder Generalizability Generalized Anxiety Disorder increasingly Intensive Internet Internet psychotherapy Intervention less main outcome measure medication medications Meta-analysis monotherapy MOST not blinded not different Panic Panic disorder participant patients performed Placebo placebos Program psychiatrist Psychological psychologist psychotherapy randomized controlled study recruited remote Research Result social anxiety disorder suggested Treatment trials [DOI] 10.1186/s12888-022-04002-1 PMC 바로가기 [Article Type] Review
SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy전신 경화증 환자의 SARS-CoV-2 백신: 질병 하위 유형 및 치료의 영향Clinical Trial Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] affected affecting anti-SARS-CoV-2 Antibody Response baseline comparable Control controls CoronaVac disease dose Factor first dose Follow-up Frequency immunogenicity immunosuppressive inactivated individual Interstitial lung disease majority median age MMF moderate monotherapy Most patient Multiple mycophenolate neutralizing antibody Participants Patient Prospective Study regression analysis respiratory safety profile SARS-CoV-2 SARS-CoV-2 vaccine Seroconversion Side-effect subgroup of patients Systemic sclerosis therapy Trial vaccination Vaccine vaccine response were assessed [DOI] 10.1093/rheumatology/keab886 PMC 바로가기 [Article Type] Clinical Trial
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients리툭시맙 치료 환자에서 COVID-19 백신 접종에 대한 체액 반응 장애의 위험 요인Observational Study Published on 2022-06-282022-09-11 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, 진단, 치료기술, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antibody antibody levels Antibody Response B cell B cells CD19 Characteristics chronic inflammatory rheumatic disorder consecutive patient consecutive patients coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 vaccination cut-off value demographics detectable disease Factor humoral Humoral response identify IgG antibody independent Inflammatory monitoring monotherapy MTX multivariate multivariate analyses negative Odds ratio Patient patients produced receiving recruited respiratory rheumatic disease Rheumatic diseases rituximab RTX SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 vaccination seroconversion rate seroconversion rates serology Seropositivity severe acute respiratory syndrome Coronavirus Spike protein Spike proteins therapy two-dose regimen undetectable usual care vaccination were measured [DOI] 10.1093/rheumatology/keab815 PMC 바로가기 [Article Type] Observational Study
Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trialResearch article Published on 2022-06-032022-10-05 Journal: EClinicalMedicine [Category] 신약개발, 임상, 치료제, [키워드] 95% CI Admission Adverse AMED assigned calculated camostat Characteristics Ciclesonide clinical Clinical finding Clinical management Combination combination therapy comparable COVID-19 COVID-19 infection deaths decrease development discharge Effectiveness enrolled evaluated event Favipiravir finding funding group groups healthcare worker hospital discharge rate Hospital stay Hospitalization Hospitalized Japan Japanese lack less limitation median time Ministry of Health monotherapy no significant difference number Open-label oxygen participant Patient patients patients with moderate Phase 3 phase 3 study Pneumonia positive Primary outcome randomized clinical trial Randomized controlled trial Randomly Registered registry Research SARS-CoV-2 Severe COVID-19 Infection significantly higher significantly lower single-center statistically supported therapy Treatment vaccination Version Welfare [DOI] 10.1016/j.eclinm.2022.101484 [Article Type] Research article